908 Devices (NASDAQ:MASS) Releases Earnings Results, Beats Expectations By $0.04 EPS

908 Devices (NASDAQ:MASS) announced its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04, FiscalAI reports. The business had revenue of $18.95 million for the quarter, compared to analysts’ expectations of $18.31 million. 908 Devices had a negative return on equity of 12.54% and a negative net margin of 56.96%.

Here are the key takeaways from 908 Devices’ conference call:

• Revenue growth accelerated and guidance increased: Q3 revenue rose 35% year over year to a record $19 million, and the company raised the low end of its 2026 revenue outlook to $68.5 million–$70 million, implying 22%–25% annual growth.
• Device adoption broadened, including internationally: 908 Devices shipped a record 300-plus devices, bringing its installed base to about 4,400; international customers accounted for 40% of Q3 revenue, supported by ProtectIR government wins and other platform demand.
• NIRLab showed early commercial traction: The company sold about 100 devices in the quarter, while platform scans surpassed 1 million cumulatively. Management sees subscriptions and broader connected services as a potential source of recurring revenue, though the business is still developing.
• Profitability improved modestly, while future growth depends on execution: Adjusted EBITDA loss was $1.7 million, and the company ended Q3 with $99.1 million in cash and no debt. Management cited the next-generation MX908 and potential 2027 AVCAD orders as growth drivers, but AVCAD revenue is excluded from 2026 guidance and reaching the upper end of the outlook depends on closing key Q4 opportunities.

908 Devices Stock Performance

Shares of NASDAQ:MASS traded down $1.44 during midday trading on Tuesday, hitting $10.07. 224,774 shares of the company’s stock traded hands, compared to its average volume of 337,609. 908 Devices has a twelve month low of $5.03 and a twelve month high of $13.35. The firm’s fifty day moving average price is $11.21 and its two-hundred day moving average price is $8.50. The company has a market cap of $416.07 million, a PE ratio of -10.47 and a beta of 0.66.

Wall Street Analyst Weigh In

A number of research firms have weighed in on MASS. Canaccord Genuity Group initiated coverage on shares of 908 Devices in a research note on Thursday, September 10th. They set a “buy” rating and a $13.50 price objective for the company. Wall Street Zen downgraded 908 Devices from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Roth Capital upped their target price on shares of 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Stifel Nicolaus lifted their price target on 908 Devices from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 908 Devices in a research report on Wednesday, November 4th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.83.

Insider Activity at 908 Devices

In other news, SVP John Kenneweg sold 5,257 shares of 908 Devices stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $10.22, for a total value of $53,726.54. Following the completion of the sale, the senior vice president owned 57,784 shares in the company, valued at $590,552.48. The trade was a 8.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Joseph H. Iv Griffith sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $13.03, for a total transaction of $65,150.00. Following the sale, the chief financial officer owned 116,497 shares of the company’s stock, valued at $1,517,955.91. This represents a 4.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 134,115 shares of company stock worth $1,473,296. Company insiders own 28.20% of the company’s stock.

About 908 Devices

908 Devices Inc is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions.

The company’s product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.